MyFinsight
Home
Blog
About
Contact
Download
Download image
Comprehensive loss
-$14,891K
Cumulative foreign
currency translation...
$409K
Net loss
-$15,283K
Unrealized gain (loss) on
marketable securities
-$17K
Loss before equity
method investment
-$13,325K
Loss from equity
method investment
-$1,958K
Change in fair value of
warrant liability
-$27,141K
Interest income and other
expense, net
$2,505K
Loss from operations
-$42,971K
Total operating
expenses
$42,971K
Research and development
$33,719K
General and
administrative
$9,252K
Back
Back
Income Statement
source: myfinsight.com
Corvus Pharmaceuticals, Inc. (CRVS)
Corvus Pharmaceuticals, Inc. (CRVS)